Erlotinib Induces Synthetic Lethality With the Poly(ADP-Ribose) Polymerase (PARP) Inhibitor ABT-888 in Esophageal Cancer

被引：1
|
作者：
Whitley, A. C. [1 ]
Jackson, J. [1 ]
Trummell, H. [1 ]
Bonner, J. [1 ]
Yang, E. S. [1 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2012年 / 84卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2012.07.428
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S165 / S166
页数：2
相关论文
共 50 条
  • [21] Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles
    Munoz-Gamez, Jose A.
    Lopez Viota, Julian
    Barrientos, Andres
    Carazo, Angel
    Sanjuan-Nunez, Laura
    Quiles-Perez, Rosa
    Munoz-de-Rueda, Paloma
    Delgado, Angel
    Ruiz-Extremera, Angeles
    Salmeron, Javier
    LIVER INTERNATIONAL, 2015, 35 (04) : 1430 - 1441
  • [22] Disposition and Drug-Drug Interaction Potential of Veliparib (ABT-888), a Novel and Potent Inhibitor of Poly(ADP-ribose) Polymerase
    Li, Xiaofeng
    Delzer, Juergen
    Voorman, Richard
    de Morais, Sonia M.
    Lao, Yanbin
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (07) : 1161 - 1169
  • [23] Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
    Appleman, Leonard J.
    Beumer, Jan H.
    Jiang, Yixing
    Lin, Yan
    Ding, Fei
    Puhalla, Shannon
    Swartz, Leigh
    Owonikoko, Taofeek K.
    Harvey, R. Donald
    Stoller, Ronald
    Petro, Daniel P.
    Tawbi, Hussein A.
    Argiris, Athanassios
    Strychor, Sandra
    Pouquet, Marie
    Kiesel, Brian
    Chen, Alice P.
    Gandara, David
    Belani, Chandra P.
    Chu, Edward
    Ramalingam, Suresh S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (06) : 1289 - 1301
  • [24] ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
    Donawho, Cherrie K.
    Luo, Yan
    Luo, Yanping
    Penning, Thomas D.
    Bauch, Joy L.
    Bouska, Jennifer J.
    Bontcheva-Diaz, Velitchka D.
    Cox, Bryan F.
    DeWeese, Theodore L.
    Dillehay, Larry E.
    Ferguson, Debra C.
    Ghoreishi-Haack, Nayereh S.
    Grimm, David R.
    Guan, Ran
    Han, Edward K.
    Holley-Shanks, Rhonda R.
    Hristov, Boris
    Idler, Kenneth B.
    Jarvis, Ken
    Johnson, Eric F.
    Kleinberg, Lawrence R.
    Klinghofer, Vered
    Lasko, Loren M.
    Liu, Xuesong
    Marsh, Kennan C.
    McGonigal, Thomas P.
    Meulbroek, Jonathan A.
    Olson, Amanda M.
    Palma, Joann P.
    Rodriguez, Luis E.
    Shi, Yan
    Stavropoulos, Jason A.
    Tsurutani, Alan C.
    Zhu, Gui-Dong
    Rosenberg, Saul H.
    Giranda, Vincent L.
    Frost, David J.
    CLINICAL CANCER RESEARCH, 2007, 13 (09) : 2728 - 2737
  • [25] A Biomarker Study of Poly(ADP-ribose) Polymerase Inhibitor (PARPi) ABT-888 Activity On Ex Vivo Tissue From Ovarian Cancer Patients
    Weberpals, J.
    Ma, X.
    Dimitroulakos, J.
    Djordjevic, B.
    Lapointe-Milot, K.
    Al Mutairi, N.
    Pelletier, L.
    Oza, A.
    Squire, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 146 - 146
  • [26] Preclinical evaluation of Poly (ADP) Ribose Polymerase (PARP) enzyme inhibitor, ABT-888, in combination with cytotoxic agents in small cell lung cancer (SCLC)
    Owonikoko, Taofeek K.
    Zhang, Guojing
    Yue, Ping
    Ramalingam, Suresh
    Khuri, Fadlo
    Sun, Shi-Yong
    CANCER RESEARCH, 2011, 71
  • [27] Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas
    Yang, Sherry X.
    Kummar, Shivaani
    Steinberg, Seth M.
    Murgo, Anthony J.
    Gutierrez, Martin
    Rubinstein, Larry
    Nguyen, Dat
    Kaur, Gurmeet
    Chen, Alice P.
    Giranda, Vincent L.
    Tomaszewski, Joseph E.
    Doroshow, James H.
    CANCER BIOLOGY & THERAPY, 2009, 8 (21) : 2004 - 2009
  • [28] Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP
    Kummar, Shivaani
    Rubinstein, Larry
    Kinders, Robert
    Ji, Jiuping
    Parchment, Ralph
    Gutierrez, Martin
    Murgo, Anthony
    Chen, Alice
    Khin, Sonny
    Zhang, Yiping
    Simmons, Dwight
    Yancey, Mary Ann
    Allen, Deborah
    Horneffer, Yvonne
    Juwara, Lamin
    Chang, Richard
    Gordon, Gary
    Tomaszewski, Joseph
    Doroshow, James
    CANCER RESEARCH, 2009, 69
  • [29] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
    LoRusso, Patricia M.
    Li, Jing
    Burger, Angelika
    Heilbrun, Lance K.
    Sausville, Edward A.
    Boerner, Scott A.
    Smith, Daryn
    Pilat, Mary Jo
    Zhang, Jie
    Tolaney, Sara M.
    Cleary, James M.
    Chen, Alice P.
    Rubinstein, Lawrence
    Boerner, Julie L.
    Bowditch, Adam
    Cai, Dongpo
    Bell, Tracy
    Wolanski, Andrew
    Marrero, Allison M.
    Zhang, Yiping
    Ji, Jiuping
    Ferry-Galow, Katherine
    Kinders, Robert J.
    Parchment, Ralph E.
    Shapiro, Geoffrey I.
    CLINICAL CANCER RESEARCH, 2016, 22 (13) : 3227 - 3237
  • [30] Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry
    Wiegand, Richard
    Wu, Jianmei
    Sha, Xianyi
    LoRusso, Patricia
    Li, Jing
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2010, 878 (3-4): : 333 - 339
12345